JORNAY PM
ADHD
MarketedGrowth & Expansion
Key Facts
About Collegium Pharmaceutical
Collegium Pharmaceutical is a publicly traded, commercial-stage biopharmaceutical company with a strategic focus on pain management and neuropsychiatry. The company has established itself through a disciplined strategy of portfolio diversification, specializing in abuse-deterrent formulations and the acquisition/commercialization of differentiated medicines. Under new leadership, Collegium is executing on a growth trajectory, aiming to strengthen its position in ADHD and expand its impact through a commitment to science, corporate responsibility, and robust commercial execution.
View full company profileTherapeutic Areas
Other ADHD Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Program | Curemark | Preclinical |
| NRCT-101SR | Neurocentria | Phase 2b/3 |
| XELSTRYM | Noven Pharmaceuticals | Approved |
| DAYTRANA | Noven Pharmaceuticals | Approved |
| QELBREE (viloxazine ER) | Supernus Pharmaceuticals | Approved |
| AZSTARYS | Collegium Pharmaceutical | Acquisition Pending |
| CTx-1301 | Cingulate | Phase 3 |
| CTx-1302 | Cingulate | Phase 3 |